Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
100%(5 trials)

Phase Distribution

Ph phase_2
5
63%
Ph not_applicable
1
13%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Other(2)

Detailed Status

Completed5
unknown2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
N/A1 (14.3%)

Trials by Status

completed563%
enrolling_by_invitation113%
unknown225%

Recent Activity

0 active trials
Showing 5 of 8
enrolling_by_invitationnot_applicable

Immunosuppressant Withdrawal Based on Parenchymal Chimerism in the Liver Transplantation

NCT07735650
completedphase_2

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

NCT02533180
unknown

Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis

NCT03711669
completedphase_2

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

NCT01638559
completedphase_2

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07735650Not Applicable

Immunosuppressant Withdrawal Based on Parenchymal Chimerism in the Liver Transplantation

Enrolling By Invitation
NCT02533180Phase 2

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

Completed
NCT03711669

Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis

Unknown
NCT01638559Phase 2

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

Completed
NCT00135694Phase 2

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

Completed
NCT00320606Phase 1

Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients

Completed
NCT00105235Phase 2

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

Completed
NCT01198314Phase 2

Withdrawal of Immunosuppression in Long Term Stable Liver Transplant Recipients

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8